Content
May 2024, Volume 42, Issue 5
- 475-478 Economic Evaluations of Treatments for Duchenne Muscular Dystrophy: The Caregiver QALY Trap
by Erik Landfeldt & Hera Sandhu - 479-486 Value of Information for Clinical Trial Design: The Importance of Considering All Relevant Comparators
by Anna Heath & Gianluca Baio & Ioanna Manolopoulou & Nicky J. Welton - 487-506 Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments
by Jen-Yu Amy Chang & James B. Chilcott & Nicholas R. Latimer - 507-526 Content Comparison of Quality-of-Life Instruments Used in Economic Evaluations of Sleep Disorder Interventions: A Systematic Review
by Billingsley Kaambwa & Taylor-Jade Woods & Andrea Natsky & Norma Bulamu & Christine Mpundu-Kaambwa & Kelly A. Loffler & Alexander Sweetman & Peter G. Catcheside & Amy C. Reynolds & Robert Adams & Danny J. Eckert - 527-568 Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review
by Angie Raad & Maria Rizzo & Katherine Appiah & Isabella Kearns & Luis Hernandez - 569-582 Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA
by Shih-Wen Lin & Sheila Shapouri & Hélène Parisé & Eric Bercaw & Mei Wu & Eunice Kim & Matthew Matasar - 583-603 Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary
by Anna Nikl & Mathieu F. Janssen & Balázs Jenei & Valentin Brodszky & Fanni Rencz - 605-606 Comment on: A Framework for the Fair Pricing of Medicines
by Zaheer-Ud-Din Babar - 607-609 Reply to Comment on “A Framework for Fair Pricing of Medicines”
by Mike Paulden
April 2024, Volume 42, Issue 4
- 363-371 A Guide to an Iterative Approach to Model-Based Decision Making in Health and Medicine: An Iterative Decision-Making Framework
by Natalia Kunst & Emily A. Burger & Veerle M. H. Coupé & Karen M. Kuntz & Eline Aas - 373-392 Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review
by Clara Marquina & Jedidiah I Morton & Melanie Lloyd & Dina Abushanab & Yeji Baek & Tamrat Abebe & Adam Livori & Padam Dahal & Gerald F. Watts & Zanfina Ademi - 393-407 An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada
by Diedron Lewis & William W. L. Wong & Joseph Lipscomb & Susan Horton - 409-418 Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
by Dong-Won Kang & Li Wang & Nicholas J. Short & Alessandra Ferrajoli & Yucai Wang & Shouhao Zhou & Chan Shen - 419-434 Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy
by Zakile A. Mfumbilwa & Martijn J. H. G. Simons & Bram Ramaekers & Valesca P. Retèl & Joanne M. Mankor & Harry J. M. Groen & Joachim G. J. V. Aerts & Manuela Joore & Janneke A. Wilschut & Veerle M. H. Coupé - 435-446 The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life
by Cate Bailey & Martin Howell & Rakhee Raghunandan & Kim Dalziel & Kirsten Howard & Brendan Mulhern & Stavros Petrou & Donna Rowen & Amber Salisbury & Rosalie Viney & Emily Lancsar & Nancy Devlin - 447-461 Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States
by Anita J. Brogan & Ashley E. Davis & Claire E. Mellott & Jeremy Fraysse & Aimee A. Metzner & Alan K. Oglesby - 463-473 The Burden of Type 2 Diabetes on the Productivity and Economy in Sub-Saharan Africa: A Life Table Modelling Analysis from a South African Perspective
by Assegid Hellebo & Andre P. Kengne & Zanfina Ademi & Olufunke Alaba
March 2024, Volume 42, Issue 3
- 249-252 Making Decision Models Fit for Purpose: The Importance of Ensuring Stakeholder Involvement
by Stephanie Harvard - 253-259 A Research Framework to Improve Health Disparity Evidence Gaps in Value Assessments
by T. Joseph Mattingly - 261-273 Estimating Costs Associated with Disease Model States Using Generalized Linear Models: A Tutorial
by Junwen Zhou & Claire Williams & Mi Jun Keng & Runguo Wu & Borislava Mihaylova - 275-299 Evaluating the Quantity and Quality of Health Economic Literature in Blinding Childhood Disorders: A Systematic Literature Review
by Lucinda J. Teoh & Salomey Kellett & Dipesh E. Patel & Mario Cortina-Borja & Ameenat Lola Solebo & Jugnoo S. Rahi - 301-318 Palliative Care Costs in Different Ambulatory-Based Settings: A Systematic Review
by Ana Helena Perea-Bello & Marta Trapero-Bertran & Christian Dürsteler - 319-328 Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid
by Antal Zemplenyi & Jim Leonard & Michael J. DiStefano & Kelly E. Anderson & Garth C. Wright & Nicholas D. Mendola & Kavita Nair & R. Brett McQueen - 329-341 Estimating the Treatment and Prophylactic Economic Value of New Antimicrobials in Managing Antibiotic Resistance and Serious Infections for Common Pathogens in the USA: A Population Modelling Study
by Jason Gordon & Maria Gheorghe & Cale Harrison & Ryan Miller & James Dennis & Lotte Steuten & Simon Goldenberg & Sumanth Gandra & Amer Al-Taie - 343-362 Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force
by Edward Henry & Hareth Al-Janabi & Werner Brouwer & John Cullinan & Lidia Engel & Susan Griffin & Claire Hulme & Pritaporn Kingkaew & Andrew Lloyd & Nalin Payakachat & Becky Pennington & Luz María Peña-Longobardo & Lisa A. Prosser & Koonal Shah & Wendy J. Ungar & Thomas Wilkinson & Eve Wittenberg
February 2024, Volume 42, Issue 2
- 133-136 Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective
by Giovany Orozco-Leal & Eugenie Evelynne Johnson & Sedighe Hosseinijebeli & Tomos Robinson & Tara Homer & Claire H. Eastaugh & Catherine Richmond & Louise Tanner & Nick Meader & Ryan Kenny & Sheila A. Wallace & Stephen Rice - 137-144 Surrogacy and the Valuation of ATMPs: Taking Our Place in the Evidence Generation/Assessment Continuum
by Daniel Gladwell & Oriana Ciani & Adam Parnaby & Stephen Palmer - 145-164 A Framework for the Fair Pricing of Medicines
by Mike Paulden - 165-176 Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments
by Alex J. Turner & Cormac Sammon & Nick Latimer & Blythe Adamson & Brennan Beal & Vivek Subbiah & Keith R. Abrams & Joshua Ray - 177-198 Systematic Review of the Relative Social Value of Child and Adult Health
by Tessa Peasgood & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Marcus Sellars & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Kirsten Howard & Emily Lancsar & Stavros Petrou & Julie Ratcliffe & Rosalie Viney & Germaine Wong & Richard Norman & Cam Donaldson - 199-217 A Systematic Review of Methods Used by Pediatric Cost-Utility Analyses to Include Family Spillover Effects
by Ramesh Lamsal & E. Ann Yeh & Eleanor Pullenayegum & Wendy J. Ungar - 219-229 Cost-Effectiveness Analysis of Vaccines for COVID-19 According to Sex, Comorbidity and Socioeconomic Status: A Population Study
by Javier Mar & Oliver Ibarrondo & Carlo Delfin S. Estadilla & Nico Stollenwerk & Fernando Antoñanzas & Rubén Blasco-Aguado & Igor Larrañaga & Joseba Bidaurrazaga & Maíra Aguiar - 231-247 Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States
by Christopher W. Yee & Michael J. Harvey & Yiqiao Xin & Noam Y. Kirson
January 2024, Volume 42, Issue 1
- 5-9 Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective
by Diarmuid Coughlan & Oluwatomi Arisa & Katie Thomson & Ge Yu & Fiona Pearson & Ashleigh Kernohan & Sonia Garcia Gonzalez-Moral & Sheila Wallace & Stephen Rice - 11-18 The Difference Method Approach for Sampling Order Constrained Parameters: An Improved Implementation and Important Limitations
by Daniel Hill-McManus - 19-40 A Systematic Review of Methodologies Used in Models of the Treatment of Diabetes Mellitus
by Marina Antoniou & Céu Mateus & Bruce Hollingsworth & Andrew Titman - 41-68 Economic Evaluations Comparing Deep Brain Stimulation to Best Medical Therapy for Movement Disorders: A Meta-Analysis
by Melissa Lannon & Taylor Duda & Alexander Mastrolonardo & Ellissa Huang & Amanda Martyniuk & Forough Farrokhyar & Feng Xie & Mohit Bhandari & Suneil K. Kalia & Sunjay Sharma - 69-90 Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada
by Aneeka Hafeez & Lauren E. Cipriano & Richard B. Kim & Gregory S. Zaric & Ute I. Schwarz & Sisira Sarma - 91-107 Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis
by Jedidiah I. Morton & Clara Marquina & Melanie Lloyd & Gerald F. Watts & Sophia Zoungas & Danny Liew & Zanfina Ademi - 109-116 Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer
by Anthony J. Hatswell & Mohammad A. Chaudhary & Giles Monnickendam & Alejandro Moreno-Koehler & Katie Frampton & James W. Shaw & John R. Penrod & Rachael Lawrance - 117-131 Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition
by Daniel Tobias Michaeli & Thomas Michaeli
December 2023, Volume 41, Issue 12
- 1553-1555 The Carer QALY Trap and Altruism in Economic Evaluations
by J. Mick Tilford & Aygul Tarlan - 1557-1561 Modelling Spillover Effects on Informal Carers: The Carer QALY Trap
by David J. Mott & Hannah Schirrmacher & Hareth Al-Janabi & Sophie Guest & Becky Pennington & Nicolas Scheuer & Koonal K. Shah & Chris Skedgel - 1563-1588 Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies
by Deborah A. Marshall & Brittany Gerber & Diane L. Lorenzetti & Karen V. MacDonald & Riley Jewel Bohach & Gillian R. Currie - 1589-1601 Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations
by Kumar Mukherjee & Necdet B. Gunsoy & Rita M. Kristy & Joseph C. Cappelleri & Jessica Roydhouse & Judith J. Stephenson & David J. Vanness & Sujith Ramachandran & Nneka C. Onwudiwe & Sri Ram Pentakota & Helene Karcher & Gian Luca Di Tanna - 1603-1615 Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens
by David Teigen & Robert O. Opoka & Phillip Kasirye & Catherine Nabaggala & Heather A. Hume & Bjørn Blomberg & Chandy C. John & Russell E. Ware & Bjarne Robberstad - 1617-1627 Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
by Boshen Jiao - 1629-1639 De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation
by Peter Gal & Gyorgyi Feldmajer & Margarida Augusto & Ray Gani & Emma Hook & Ash Bullement & Zoe Philips & Inger Smith - 1641-1655 Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
by Michaela Carla Barbier & Alicia Fengler & Esther Pardo & Arjun Bhadhuri & Niklaus Meier & Oliver Gautschi - 1657-1673 Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom
by Jason Gordon & Maria Gheorghe & Simon Goldenberg & Ryan Miller & James Dennis & Amer Al-Taie
November 2023, Volume 41, Issue 11
- 1403-1413 Conducting Trial-Based Economic Evaluations Using R: A Tutorial
by Ângela Jornada Ben & Johanna M. Dongen & Mohamed El Alili & Jonas L. Esser & Hana Marie Broulíková & Judith E. Bosmans - 1415-1435 Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review
by Katja C. Heinz & Charlotte Beaudart & Damon Willems & Isabell Wiethoff & Mickaël Hiligsmann - 1437-1452 Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)
by Nick Jovanoski & Seye Abogunrin & Danilo Di Maio & Rossella Belleli & Pollyanna Hudson & Sneha Bhadti & Libby G. Jones - 1453-1467 Economic and Humanistic Burden of Osteoarthritis: An Updated Systematic Review of Large Sample Studies
by Xuejing Jin & Wanxian Liang & Lining Zhang & Shihuan Cao & Lujia Yang & Feng Xie - 1469-1514 A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
by Henrik Vitus Bering Laursen & Emmelie Ploug Jørgensen & Peter Vestergaard & Lars Holger Ehlers - 1515-1524 EQ-5D-5L Value Set for Slovenia
by Valentina Prevolnik Rupel & Marko Ogorevc - 1525-1537 Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia
by Preston Ngo & Deme Karikios & David Goldsbury & Stephen Wade & Zarnie Lwin & Brett G. M. Hughes & Kwun M. Fong & Karen Canfell & Marianne Weber - 1539-1550 Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model
by Kathrin Pahmeier & Christian Speckemeier & Silke Neusser & Jürgen Wasem & Janine Biermann-Stallwitz - 1551-1551 Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Thomas Otten & Rob Riemsma & Ben Wijnen & Nigel Armstrong & Lisa Stirk & Caroline Gordon & Bram Ramaekers & Jos Kleijnen & Manuela Joore & Sabine Grimm
October 2023, Volume 41, Issue 10
- 1165-1174 Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
by Nancy J. Devlin & Tianxin Pan & Mark Sculpher & Mark Jit & Elly Stolk & Donna Rowen & Barend Hout & Richard Norman - 1175-1182 An Alternative Measure of Health for Value Assessment: The Equal Value Life-Year
by Jonathan D. Campbell & Melanie D. Whittington & Steven D. Pearson - 1183-1203 Health Economic Research Assessing the Value of Early Detection of Cardiovascular Disease: A Systematic Review
by Martijn J. Oude Wolcherink & Carina M. Behr & Xavier G. L. V. Pouwels & Carine J. M. Doggen & Hendrik Koffijberg - 1205-1228 Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease: An Updated Methodological Review
by Judith Dams & Johann-Jacob Zapp & Hans-Helmut König - 1229-1248 Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review
by Mussab Fagery & Hadi A. Khorshidi & Stephen Q. Wong & Martin Vu & Maarten IJzerman - 1249-1262 Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
by Xinyu Li & Rudolf Hoogenveen & Mohamed El Alili & Saskia Knies & Junfeng Wang & Joline W. J. Beulens & Petra J. M. Elders & Giel Nijpels & Anoukh Giessen & Talitha L. Feenstra - 1263-1274 Modeling Monthly Migraine-Day Distributions Using Longitudinal Regression Models and Linking Quality of Life to Inform Cost-Effectiveness Analysis: A Case Study of Fremanezumab in Japanese-Korean Migraine Patients
by Xinyu Wang & Kentaro Yamato & Yoshitsugu Kojima & Josef J. Paris & Elisabeth F. P. Peterse & Martijn J. H. G. Simons & Craig Bennison - 1275-1286 Context-Specific Estimation of Future Unrelated Medical Costs and Their Impact on Cost-Effectiveness Analyses
by Noga Epstein & Tzahit Simon-Tuval & Yakir Berchenko - 1287-1388 Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA
by Michael Falk Hvidberg & Mónica Hernández Alava - 1389-1402 Jumping the Queue:Willingness to Pay for Faster Access to COVID-19 Vaccines in Seven European Countries
by Sebastian Neumann-Böhme & Iryna Sabat & Carolin Brinkmann & Arthur E. Attema & Tom Stargardt & Jonas Schreyögg & Werner Brouwer
September 2023, Volume 41, Issue 9
- 1027-1030 Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs
by Werner Brouwer & Pieter Baal - 1031-1050 Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review
by Marieke Krol & Nikkie Hosseinnia & Werner Brouwer & Leona Hakkaart Roijen - 1051-1064 Measuring the Indirect Cost of Illness Using EQ-5D-5L While Accounting for Job Characteristics
by Beata Koń & Michał Jakubczyk - 1065-1077 Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis
by Boshen Jiao & Anirban Basu - 1079-1091 Productivity Loss Across Socioeconomic Groups Among Patients With Low Back Pain or Osteoarthritis: Estimates Using the Friction-Cost Approach in Norway
by Johan A. Liseth Hansen & Thomas Fast & Knut Reidar Wangen - 1093-1101 Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries
by Paul Hanly & Marta Ortega Ortega & Alison Pearce & Marianna Camargo Cancela & Isabelle Soerjomataram & Linda Sharp - 1103-1115 Production Losses due to Absenteeism and Presenteeism: The Influence of Compensation Mechanisms and Multiplier Effects
by Werner Brouwer & Kaya Verbooy & Renske Hoefman & Job Exel - 1117-1136 Informal Caregiving Provision for Disabled or Elderly in the Families and Work Productivity: Evidence from 11 Waves of an Australian Population-Based Cohort
by Syed Afroz Keramat & Rubayyat Hashmi & Bolaji Samson Aregbeshola & Tracy Comans - 1137-1149 Informal Care Costs According to Age and Proximity to Death to Support Cost-Effectiveness Analyses
by Saskia Groot & Irene Santi & Pieter Bakx & Bram Wouterse & Pieter Baal - 1151-1164 Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy
by David D. Kim
August 2023, Volume 41, Issue 8
- 843-844 Time to Close the Gap Between Guidelines and the Reimbursement Policy for Diabetes Treatment in Turkey
by Alper Tuna Güven - 845-856 How Much Better is Faster? Value Adjustments for Health-Improvement Sequences
by F. Reed Johnson & Juan Marcos Gonzalez & John J. Sheehan & Shelby D. Reed - 857-867 Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Willem Witlox & Sabine Grimm & Jeremy Howick & Nigel Armstrong & Charlotte Ahmadu & Kevin McDermott & Thomas Otten & Caro Noake & Robert Wolff & Manuela Joore - 869-911 Cost-Effectiveness of Thrombopoietin Mimetics in Patients with Thrombocytopenia: A Systematic Review
by Hans Van Remoortel & Hans Scheers & Bert Avau & Jørgen Georgsen & Susan Nahirniak & Nadine Shehata & Simon J. Stanworth & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 913-943 Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review
by Charles Okafor & Joshua Byrnes & Simon Stewart & Paul Scuffham & Clifford Afoakwah - 945-980 A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
by Lara Chayab & Natalia Konstantelos & Natasha B. Leighl & Mina Tadrous & William W. L. Wong - 981-997 Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
by Marianne Luyendijk & Agnes Jager & Sanne M. Buijs & Sabine Siesling & Carin A. Uyl-de Groot & Hedwig M. Blommestein - 999-1010 Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)
by Maria Jesus Rodríguez-Nieto & Esteban Cano-Jiménez & Ana D. Romero Ortiz & Ana Villar & Marta Morros & Alba Ramon & Silvia Armengol - 1011-1025 Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers
by Aurelie Meunier & Louise Longworth & Manuel Gomes & Sreeram Ramagopalan & Louis P. Garrison & Sanjay Popat
July 2023, Volume 41, Issue 7
- 733-740 Patient and Public Involvement in Health Economics Modelling Raises the Need for Normative Guidance
by Stephanie Harvard & Eric Winsberg - 741-750 Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Giovany Orozco Leal & Nigel Armstrong & Ashleigh Kernohan & Charlotte Ahmadu & Diarmuid Coughlan & Kevin McDermott & Steven Duffy & Susan O’Meara & Tomos Robinson & Luke Vale & Jos Kleijnen - 751-769 Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature
by Daniel D. Joyce & Vidit Sharma & Stephen B. Williams - 771-785 Economic Impact of Insufficient and Disturbed Sleep in the Workplace
by Danielle R. Glick & Samuel A. Abariga & Irine Thomas & Andrea G. Shipper & Brian C. Gunia & Michael A. Grandner & Elliot Rosenberg & Stella E. Hines & Vincent Capaldi & Jacob Collen & Emerson M. Wickwire - 787-802 Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward
by Sergio Torres-Rueda & Fern Terris-Prestholt & Mitzy Gafos & Pitchaya Peach Indravudh & Rebecca Giddings & Fiammetta Bozzani & Matthew Quaife & Lusine Ghazaryan & Carlyn Mann & Connie Osborne & Matthew Kavanagh & Peter Godfrey-Faussett & Graham Medley & Shelly Malhotra - 803-818 Developing a Framework of Cost Elements of Socioeconomic Burden of Rare Disease: A Scoping Review
by Gillian R. Currie & Brittany Gerber & Diane Lorenzetti & Karen MacDonald & Susanne M. Benseler & Francois P. Bernier & Kym M. Boycott & K. Vanessa Carias & Bettina Hamelin & Robin Z. Hayeems & Claire LeBlanc & Marinka Twilt & Gijs Rooijen & Durhane Wong-Rieger & Rae S. M. Yeung & Deborah A. Marshall - 819-830 Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States
by Mickaël Hiligsmann & Stuart S. Silverman & Andrea J. Singer & Leny Pearman & Jake Mathew & Yamei Wang & John Caminis & Jean-Yves Reginster - 831-841 Decomposition of Quality-Adjusted Life Expectancy Inequalities by Mortality and Health-Related Quality of Life Dimensions
by James Love-Koh & Paul Schneider & Simon McNamara & Tim Doran & Nils Gutacker
June 2023, Volume 41, Issue 6
- 607-617 The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice
by Bram Wouterse & Pieter Baal & Matthijs Versteegh & Werner Brouwer - 619-632 Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
by Thomas Michael Otten & Sabine E. Grimm & Bram Ramaekers & Manuela A. Joore - 633-650 Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review
by Olena Mandrik & Anne I. Hahn & James W. F. Catto & Ann G. Zauber & Marcus Cumberbatch & James Chilcott - 651-673 Cost Effectiveness of Pharmacological and Non-pharmacological Treatments for Depression in Low- and Middle-Income Countries: A Systematic Literature Review
by Yared Belete Belay & Lidia Engel & Yong Yi Lee & Ngoc Le & Cathrine Mihalopoulos - 675-692 Capturing the Impact of Constraints on the Cost-Effectiveness of Cell and Gene Therapies: A Systematic Review
by Sean P. Gavan & Stuart J. Wright & Fiona Thistlethwaite & Katherine Payne - 693-707 Infectious Disease Modelling of HIV Prevention Interventions: A Systematic Review and Narrative Synthesis of Compartmental Models
by Rebecca Giddings & Pitchaya Indravudh & Graham F. Medley & Fiammetta Bozzani & Mitzy Gafos & Shelly Malhotra & Fern Terris-Prestholt & Sergio Torres-Rueda & Matthew Quaife - 709-718 Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
by Prajakta P. Masurkar & Haluk Damgacioglu & Ashish A. Deshmukh & Meghana V. Trivedi - 719-732 Projecting the Health and Economic Burden of Cardiovascular Disease Among People with Type 2 Diabetes, 2022–2031
by Dina Abushanab & Clara Marquina & Jedidiah I. Morton & Daoud Al-Badriyeh & Melanie Lloyd & Dianna J. Magliano & Danny Liew & Zanfina Ademi
May 2023, Volume 41, Issue 5
- 467-480 Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review
by Fiammetta M. Bozzani & Fern Terris-Prestholt & Matthew Quaife & Mitzy Gafos & Pitchaya P. Indravudh & Rebecca Giddings & Graham F. Medley & Shelly Malhotra & Sergio Torres-Rueda - 481-497 Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
by Kris Doggen & Albert Jan van Hoek & Jeroen Luyten - 499-527 Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review
by Emily R. Strouphauer & Olivia J. Morris & Keaton J. Soileau & Andrew D. Wiese & Troy Quast & Wayne K. Goodman & Sameer A. Sheth & Katharine D. Wojcik & Andrew G. Guzick & Eric A. Storch - 529-545 HTA Barriers for Conditional Approval Drugs
by Mackenzie Mills - 547-559 Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK
by Junwen Zhou & Runguo Wu & Claire Williams & Jonathan Emberson & Christina Reith & Anthony Keech & John Robson & Kenneth Wilkinson & Jane Armitage & Alastair Gray & John Simes & Colin Baigent & Borislava Mihaylova - 561-572 How to Predict Drug Expenditure: A Markov Model Approach with Risk Classes
by Valeska Hofbauer-Milan & Stefan Fetzer & Christian Hagist - 573-587 The Cost of Uncontrolled Blood Pressure in Australian General Practice: A Modelling Study Using Electronic Health Records (MedicineInsight)
by Jacqueline Roseleur & David A. Gonzalez-Chica & Gillian Harvey & Nigel P. Stocks & Jonathan Karnon - 589-604 Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
by Taku Kobayashi & Masato Hoshi & Akira Yuasa & Shoko Arai & Mitsunobu Ikeda & Hiroyuki Matsuda & Seok-Won Kim & Toshifumi Hibi - 605-605 Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
by Hardik Goswami & Adnan Alsumali & Yiling Jiang & Matthias Schindler & Elizabeth R. Duke & Joshua Cohen & Andrew Briggs & Amy Puenpatom
April 2023, Volume 41, Issue 4
- 339-351 Modelling the Cost-Effectiveness of Diagnostic Tests
by Tristan Snowsill - 353-361 Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Mohamed N. M. T. Al Khayat & Nigel Armstrong & Jeremy Howick & Susan O’Meara & Pawel Posadzki & Steve Ryder & Charlotte Ahmadu & Stefan R. A. Konings & Maarten J. Postma & Steven Duffy & Robert F. Wolff & Antoinette D. I. Asselt - 363-391 Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
by Nannan Li & Charlotte Beaudart & Jane A. Cauley & Steven W. Ing & Nancy E. Lane & Jean-Yves Reginster & Stuart Silverman & Andrea J. Singer & Mickaël Hiligsmann - 393-393 Correction to: Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
by Nannan Li & Charlotte Beaudart & Jane A. Cauley & Steven W. Ing & Nancy E. Lane & Jean‑Yves Reginster & Stuart Silverman & Andrea J. Singer & Mickaël Hiligsmann - 395-411 Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations
by Carina M. Behr & Martijn J. Oude Wolcherink & Maarten J. IJzerman & Rozemarijn Vliegenthart & Hendrik Koffijberg - 413-425 Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario
by John J. Kim & Wasem Alsabbagh & William W. L. Wong - 427-438 The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for Australia
by Richard Norman & Brendan Mulhern & Emily Lancsar & Paula Lorgelly & Julie Ratcliffe & Deborah Street & Rosalie Viney - 439-455 Identifying Attributes for a Value Assessment Framework in China: A Qualitative Study
by Mengmeng Zhang & Yun Bao & Yi Yang & Melissa Kimber & Mitchell Levine & Feng Xie - 457-466 Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis
by Praveen Thokala & Pann Ei Hnynn Si & Monica Hernandez Alava & Alessandro Sasso & Thilo Schaufler & Marco Soro & James Fotheringham
March 2023, Volume 41, Issue 3
- 227-237 Living Health Technology Assessment: Issues, Challenges and Opportunities
by Praveen Thokala & Tushar Srivastava & Robert Smith & Shijie Ren & Melanie D. Whittington & Jamie Elvidge & Ruth Wong & Lesley Uttley - 239-251 Filgotinib for Treating Moderately to Severely Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Antoinette D. I. Asselt & Nigel Armstrong & Merel Kimman & Andrea Peeters & Kevin McDermott & Lisa Stirk & Charlotte Ahmadu & Tim M. Govers & Frank Hoentjen & Manuela A. Joore & Sabine E. Grimm - 253-273 Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review
by Marie-Hélène Blanchet Zumofen & Jeff Frimpter & Svenn Alexander Hansen - 275-293 Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review
by Erik Landfeldt & Sophia Abner & Astrid Pechmann & Thomas Sejersen & Hugh J. McMillan & Hanns Lochmüller & Janbernd Kirschner - 295-306 Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment
by Yuqiong Lu & Zhanjing Dai & Feng Chang & Li Wang & Jiafang He & Penghua Shi & Haitao Zhang & Yun Lu - 307-319 Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy
by Chen-Han Chueh & Yi-Wen Tsai & Zi-Rong Chen & Ming-Neng Shiu & Yu-Wen Wen & Nai-Jung Chiang - 321-327 Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?
by R. Brett McQueen & Kelly E. Anderson & Joseph F. Levy & Josh J. Carlson - 329-338 The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned
by Sahar Al Shabasy & Bram Roudijk & Maggie Abbassi & Aureliano Finch & Elly Stolk & Samar Farid
February 2023, Volume 41, Issue 2
- 119-121 Best Practices: A Collection of Systematic Critical Reviews of Modeling Approaches in Specific Disease Areas
by J. Jaime Caro - 123-138 How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe
by Tuba Saygın Avşar & Xiaozhe Yang & Paula Lorgelly - 139-153 The Societal Cost of Schizophrenia: An Updated Systematic Review of Cost-of-Illness Studies
by Claire Lin & Xiaoyu Zhang & Huajie Jin - 155-174 Psychometric Properties of Generic Preference-Weighted Measures for Children and Adolescents: A Systematic Review
by Rachel Lee-Yin Tan & Sonia Zhi Yi Soh & Le Ann Chen & Michael Herdman & Nan Luo - 175-186 Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement
by Amy Gye & Stephen Goodall & Richard Abreu Lourenco - 187-198 Mapping the Patient-Reported Outcomes Measurement Information System (PROMIS-29) to EQ-5D-5L
by Mona Aghdaee & Yuanyuan Gu & Kompal Sinha & Bonny Parkinson & Rajan Sharma & Henry Cutler - 199-207 Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population Study
by Mónica Hernández Alava & Steve Pudney & Allan Wailoo - 209-225 Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
by Carla Rognoni & Camilla Falivena & Francesco Costa & Patrizio Armeni
January 2023, Volume 41, Issue 1
- 5-19 Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial
by Nathan Green & Felicity Lamrock & Nichola Naylor & Jack Williams & Andrew Briggs - 21-32 Extensions of Health Economic Evaluations in R for Microsoft Excel Users: A Tutorial for Incorporating Heterogeneity and Conducting Value of Information Analyses
by Nichola R. Naylor & Jack Williams & Nathan Green & Felicity Lamrock & Andrew Briggs - 33-42 Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Ben Wijnen & Willem Witlox & Robert Wolff & Debra Fayter & Bram Ramaekers & Thomas Otten & Steve Ryder & Pawel Posadzki & Gill Worthy & Lisa Stirk & Nigel Armstrong & Jos Kleijnen & Manuela Joore - 43-57 Patient Preferences in Targeted Pharmacotherapy for Cancers: A Systematic Review of Discrete Choice Experiments
by Shan Jiang & Ru Ren & Yuanyuan Gu & Varinder Jeet & Ping Liu & Shunping Li - 59-75 The Costs of Dementia in Europe: An Updated Review and Meta-analysis
by Linus Jönsson & Ashley Tate & Oskar Frisell & Anders Wimo - 77-91 Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures
by Siobhan Botwright & Ei Mon Win & Nattiya Kapol & Sirikanlaya Benjawan & Yot Teerawattananon - 93-105 Health-Related Quality-of-Life Outcomes of Very Preterm or Very Low Birth Weight Adults: Evidence From an Individual Participant Data Meta-Analysis
by Corneliu Bolbocean & Sylvia Pal & Stef Buuren & Peter J. Anderson & Peter Bartmann & Nicole Baumann & Jeanie L. Y. Cheong & Brian A. Darlow & Lex W. Doyle & Kari Anne I. Evensen & John Horwood & Marit S. Indredavik & Samantha Johnson & Neil Marlow & Marina Mendonça & Yanyan Ni & Dieter Wolke & Lianne Woodward & Erik Verrips & Stavros Petrou - 107-117 Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service
by Pierluigi Russo & Matteo Zanuzzi & Angelica Carletto & Annalisa Sammarco & Federica Romano & Andrea Manca
December 2022, Volume 40, Issue 12
- 1131-1142 Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries
by Leah Z. Rand & Aaron S. Kesselheim - 1143-1158 Economic Implications of Endometriosis: A Review
by Josep Darbà & Alicia Marsà - 1159-1186 A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia
by Rumjhum Agrawal & Joao Vieira & Jacqueline Ryan & Harish Negi & Tanvi Rajput & Regina Corbin & Ricardo Viana - 1187-1205 Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
by Xinyue Dong & Xiaoning He & Jing Wu - 1207-1220 Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial
by Edna Keeney & Sabina Sanghera & Richard M. Martin & Roman Gulati & Fredrik Wiklund & Eleanor I. Walsh & Jenny L. Donovan & Freddie Hamdy & David E. Neal & J. Athene Lane & Emma L. Turner & Howard Thom & Mark S. Clements - 1221-1234 Conceptual Framework for Optimised Proxy Value Set Selection Through Supra-National Value Set Development for the EQ-5D Instruments
by Agata Łaszewska & Ayesha Sajjad & Jan Busschbach & Judit Simon & Leona Hakkaart-van Roijen - 1235-1246 Efficiency of the EmERGE Pathway of Care in Five European HIV Centres
by Eduard J. Beck & Sundhiya Mandalia & Platon Yfantopoulos & Agathe Leon & Marie J. Merino & Felipe Garcia & Marie Wittevogel & Ludwig Apers & Ivana Benkovic & Sime Zekan & Josip Begovac & Ana S. Cunha & Eugenio Teofilo & Goncalo Rodrigues & Margarida D. F. Borges & Duncan Fatz & Jamie Vera & Jennifer Whetham - 1247-1259 Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective
by Tingting Qu & Shujing Zhang & Yichen Zhong & Yang Meng & He Guo & Seongjung Joo & Peter C. Enzinger - 1261-1263 Comment on “An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
by Bhaskar Rege & James McGrory & Sabina Gasper & David McDonnell - 1265-1267 Response to Comment on “An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia”
by Marjanne A. Piena & Natalie Houwing & Carla W. Kraan & Xiaofeng Wang & Heidi Waters & Craig Bennison
November 2022, Volume 40, Issue 11
- 1015-1032 A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process
by Fang Li & Frederike Jörg & Xinyu Li & Talitha Feenstra - 1033-1042 Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation
by Zanfina Ademi & Jedidiah I. Morton & Danny Liew & Stephen J. Nicholls & Sophia Zoungas & Brian A. Ference - 1043-1067 Are We Agreed? Self- Versus Proxy-Reporting of Paediatric Health-Related Quality of Life (HRQoL) Using Generic Preference-Based Measures: A Systematic Review and Meta-Analysis
by Diana Khanna & Jyoti Khadka & Christine Mpundu-Kaambwa & Kiri Lay & Remo Russo & Julie Ratcliffe - 1069-1079 Valuing the Quality-of-Life Aged Care Consumers (QOL-ACC) Instrument for Quality Assessment and Economic Evaluation
by Julie Ratcliffe & Siobhan Bourke & Jinhu Li & Brendan Mulhern & Claire Hutchinson & Jyoti Khadka & Rachel Milte & Emily Lancsar - 1081-1093 Is EQ-5D-5L Better Than EQ-5D-3L Over Time? A Head-to-Head Comparison of Responsiveness of Descriptive Systems and Value Sets from Nine Countries
by Mathieu F. Janssen & Ines Buchholz & Dominik Golicki & Gouke J. Bonsel - 1095-1105 A Proposal of a Cost-Effectiveness Modeling Approach for Heart Failure Treatment Assessment: Considering the Short- and Long-Term Impact of Hospitalization on Event Rates
by Gian Luca Di Tanna & Blake Angell & Michael Urbich & Peter Lindgren & Thomas A. Gaziano & Gary Globe & Björn Stollenwerk - 1107-1117 The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA
by Ali Tafazzoli & Scott D. Ramsey & Alissa Shaul & Ameya Chavan & Weicheng Ye & Anuraag R. Kansal & Josh Ofman & A. Mark Fendrick - 1119-1130 Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived Experience
by Mackenzie Wilson & Kednapa Thavorn & Terry Hawrysh & Ian D. Graham & Harold Atkins & Natasha Kekre & Doug Coyle & Manoj M. Lalu & Dean A. Fergusson & Kelvin K. W. Chan & Daniel A. Ollendorf & Justin Presseau
October 2022, Volume 40, Issue 10
- 931-941 Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions
by Reka E. Pataky & Stirling Bryan & Mohsen Sadatsafavi & Stuart Peacock & Dean A. Regier - 943-956 Current Practices for Accounting for Preference Heterogeneity in Health-Related Discrete Choice Experiments: A Systematic Review
by Suzana Karim & Benjamin M. Craig & Caroline Vass & Catharina G. M. Groothuis-Oudshoorn - 957-969 China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population
by Jing Wu & Xiaoning He & Pinan Chen & Shitong Xie & Xue Li & Hao Hu & Kun Zhao & Feng Xie - 971-977 Collaborating with Patient Partners to Model Clinical Care Pathways in Major Depressive Disorder: The Benefits of Mixing Evidence and Lived Experience
by Mary Bunka & Shahzad Ghanbarian & Linda Riches & Ginny Landry & Louisa Edwards & Alison M. Hoens & Stirling Bryan - 979-988 Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
by Jing Voon Chen & James C. Gahn & Jeffrey Nesheim & Paul N. Mudd, - 989-1003 A Comparison of the Content and Consistency of Methodological Quality and Transferability Checklists for Reviewing Model-Based Economic Evaluations
by Ka Keat Lim & Rositsa Koleva-Kolarova & Julia Fox-Rushby - 1005-1009 Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network
by Stephanie Harvard & Amin Adibi & Adam Easterbrook & Gregory R. Werker & David Murphy & Don Grant & Alison Mclean & Zhina Majdzadeh & Mohsen Sadatsafavi - 1011-1012 Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
by Nikolaos Giannelos & Marie Libérée Nishimwe & Nicolas Lecrenier - 1013-1014 Authors’ Reply to Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison Between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
by Joke Bilcke & Philippe Beutels
September 2022, Volume 40, Issue 9
- 837-850 Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations
by Becky Pennington & Jack Eaton & Anthony J Hatswell & Helen Taylor - 851-861 Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Thomas Otten & Rob Riemsma & Ben Wijnen & Nigel Armstrong & Lisa Stirk & Caroline Gordon & Bram Ramaekers & Jos Kleijnen & Manuela Joore & Sabine Grimm - 863-882 A Systematic Review of the Methodologies and Modelling Approaches Used to Generate International EQ-5D-5L Value Sets
by Donna Rowen & Clara Mukuria & Emily McDool - 883-899 Best–Worst Scaling and the Prioritization of Objects in Health: A Systematic Review
by Ilene L. Hollin & Jonathan Paskett & Anne L. R. Schuster & Norah L. Crossnohere & John F. P. Bridges - 901-915 Does the Structure Matter? An External Validation and Health Economic Results Comparison of Event Simulation Approaches in Severe Obesity
by Björn Schwander & Klaus Kaier & Mickaël Hiligsmann & Silvia Evers & Mark Nuijten - 917-928 The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada
by Christopher Hillis & Colin Vicente & Graeme Ball - 929-930 Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
by Afschin Gandjour
August 2022, Volume 40, Issue 8
- 743-750 A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes
by Ágnes Benedict & Emily R. Hankosky & Kinga Marczell & Jieling Chen & David J. Klein & J. Jaime Caro & Jay P. Bae & Brian D. Benneyworth - 751-776 The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review
by Michal Witkowski & Søren Ilsøe Moreno & João Fernandes & Pierre Johansen & Margarida Augusto & Sunita Nair - 777-790 Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective
by Keith W. Pratz & Xinglei Chai & Jipan Xie & Lei Yin & Xiaoyu Nie & Melissa Montez & Erica Iantuono & Lisa Downs & Esprit Ma - 791-806 Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease
by Katya Galactionova & Paola Salari & Renato Mattli & Yael Rachamin & Rahel Meier & Matthias Schwenkglenks - 807-821 Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia
by Rachel Song & Varinder Jeet & Rajan Sharma & Martin Hoyle & Bonny Parkinson - 823-833 The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance
by Simon Pol & Danielle E. M. C. Jansen & Alike W. Velden & Christopher C. Butler & Theo J. M. Verheij & Alex W. Friedrich & Maarten J. Postma & Antoinette D. I. Asselt - 835-835 Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease
by Katya Galactionova & Paola Salari & Renato Mattli & Yael Rachamin & Rahel Meier & Matthias Schwenkglenks
July 2022, Volume 40, Issue 7
- 647-652 Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers
by Jakub P. Hlávka & Tara A. Lavelle & Peter J. Neumann & Pei-Jung Lin - 653-661 Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights
by Marco Boeri & Brett Hauber & Joseph C. Cappelleri - 663-698 Preference Elicitation Techniques Used in Valuing Children’s Health-Related Quality-of-Life: A Systematic Review
by Cate Bailey & Martin Howell & Rakhee Raghunandan & Amber Salisbury & Gang Chen & Joanna Coast & Jonathan C. Craig & Nancy J. Devlin & Elisabeth Huynh & Emily Lancsar & Brendan J. Mulhern & Richard Norman & Stavros Petrou & Julie Ratcliffe & Deborah J. Street & Kirsten Howard & Rosalie Viney - 699-714 Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
by Hardik Goswami & Adnan Alsumali & Yiling Jiang & Matthias Schindler & Elizabeth R. Duke & Joshua Cohen & Andrew Briggs & Amy Puenpatom - 715-724 Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
by Yichen Zhang & Yuxuan Wei & Huangqianyu Li & Yixuan Chen & Yiran Guo & Sheng Han & Luwen Shi & Xiaodong Guan - 725-737 Clinical Benefit and Cost Effectiveness of Risk-Stratified Gastric Cancer Screening Strategies in China: A Modeling Study
by Shuxia Qin & Xuehong Wang & Sini Li & Chongqing Tan & Xiaohui Zeng & Xia Luo & Lidan Yi & Liubao Peng & Meiyu Wu & Ye Peng & Liting Wang & Xiaomin Wan - 739-740 Risk-Adjusted Performance Measures: A Comment on Elbasha
by Pedram Sendi & Matthias Schwenkglenks - 741-742 Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”
by Elamin H. Elbasha
June 2022, Volume 40, Issue 6
- 577-586 Target Trial Emulation for Transparent and Robust Estimation of Treatment Effects for Health Technology Assessment Using Real-World Data: Opportunities and Challenges
by Manuel Gomes & Nick Latimer & Marta Soares & Sofia Dias & Gianluca Baio & Nick Freemantle & Dalia Dawoud & Allan Wailoo & Richard Grieve - 587-599 Disease-Related Costs Published in The Middle East and North Africa Region: Systematic Review and Analysis of Transferability
by Zsombor Zrubka & Márta Péntek & Lea Mhanna & Teebah Abu-Zahra & Mohamed Mahdi-Abid & Meriem Fgaier & Faris El-Dahiyat & Hana Al-Abdulkarim & Michael Drummond & László Gulácsi - 601-609 Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations
by Don Husereau & Michael Drummond & Federico Augustovski & Esther Bekker-Grob & Andrew H. Briggs & Chris Carswell & Lisa Caulley & Nathorn Chaiyakunapruk & Dan Greenberg & Elizabeth Loder & Josephine Mauskopf & C. Daniel Mullins & Stavros Petrou & Raoh-Fang Pwu & Sophie Staniszewska - 611-621 A Comparison of Methods for Identifying Informal Carers: Self-Declaration Versus a Time Diary
by Sean Urwin & Yiu-Shing Lau & Gunn Grande & Matt Sutton